Expert Highlights Potential Markers of Nivolumab/Ipilimumab Response in Melanoma
Source: OncLive, December 2019
Subgroup analyses from the phase III CheckMate-067 trial identified potential biomarkers in patients who achieved a complete response (CR) with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) but later progressed, according to Georgina V. Long, BSc, PhD, MBBS, FRACP.1 Now, investigators are working to answer more questions about this group of patients.
“We are planning to try and understand more about the patients who are doing really well at 5 years,” said Long. “We are doing what we call a regression analysis to understand what major features at baseline play into why or why not a patient will be alive at 5 years.”
In CheckMate-067, patients with previously untreated stage III or IV melanoma were randomized 1:1:1 to receive either the combination of nivolumab and ipilimumab followed by nivolumab; ipilimumab alone; or nivolumab monotherapy.